• br Perspective AA LA and other PUFAs

  2023-09-05

  

  Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path

• br Current therapies for metabolic diseases Inborn errors

  2023-09-05

  

  Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m

• To further clarify the vascular cell

  2023-09-05

  

  To further clarify the vascular cell types expressing AR subtypes, double immunofluorescence staining for ARs and vascular endothelial VX-702 receptor or vascular smooth muscles was performed. As shown in Fig. 3, Fig. 4, overlay images show the expression of all ARs subtypes that we examined in vas

• The next level of possible correlation and comparison betwee

  2023-09-05

  

  The next level of possible correlation and comparison between the α7 and 5HT3 receptors is at the subunit arrangement and protein folding. Crystal structures of the nicotinic and serotoninergic 6 his receptors [45], [46] reinforced the concept of similarities between these families of receptors. Na

• hydroxydopamine OHDA is a selective catecholaminergic

  2023-09-04

  

  6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and

• Song et al reported series of triazolylsalicylamide derivati

  2023-09-04

  

  Song et al. reported series of 1,2,3-triazolylsalicylamide derivatives and screened over kinase panel and found compound 31 as most potent which inhibited Aurora-A, specifically with IC50 of 0.37 μM. Compound 31 was about 10-fold more active for Aurora-A than for Aurora-B (IC50 = 3.58 μM reported se

• Because the V ATPase inhibitors that have been

  2023-09-04

  

  Because the V-ATPase inhibitors that have been employed in these studies (including bafilomycin and concanamycin), are membrane permeant, they inhibit all the V-ATPases in the cell. This is important since it is possible that intracellular V-ATPases, in addition to those present at the plasma membra

• To maintain ATP levels postmortem

  2023-09-04

  

  To maintain ATP levels, postmortem muscle mobilizes its glycogen reserves to yield influenza a virus 6-phsphate that proceeds through glycolysis. Glycogen degradation was affected by the interaction between treatment and time (Pinitiation of the experiment. We expected that if myosin ATPase is lim

• Acl converts cytosolic citrate CoA

  2023-09-04

  

  Acl converts cytosolic citrate, CoA and ATP into acetyl-CoA, ADP+Pi and oxaloacetate (Fig. 1). This cytosolic enzyme is present in few Prokaryotes and in all Eukaryotes, but not in non-oleaginous yeasts [14]. Thus, this enzyme was presumed to be essential for FA synthesis [1], [13], [15]. In most mi

• Loss of expression or functional activity of cell adhesion

  2023-09-04

  

  Loss of expression or functional activity of cell adhesion is intricately related to advanced stages of tumour progression and invasiveness. Martin-Belmonte and Perez-Moreno recently mentioned that the deregulation of adhesion can alter tumourgenesis in the early stage. We have shown for the first t

• br Small molecule homoisoflavonoid in combination with anti

  2023-09-04

  

  Small molecule homoisoflavonoid in combination with anti-VEGF therapy Basavarajappa et al. [11] reported a new synthetic homoisoflavonoid compound, SH-11037 by modifying the structure of naturally occurring homoisoflavonoid cremastranone. SH-11037 exhibited promising inhibition of human retinal m

• br Eprosartan The AT R antagonist

  2023-09-04

  

  Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential Betamethasone Dipropionate and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovasc

• Since non lipoprotein derived free cholesterol is recycled

  2023-09-04

  

  Since non-lipoprotein-derived free cholesterol is recycled from the plasma membrane through the endosomal system through receptor-independent mechanisms, we wanted to determine whether ABCA2 could alter the trafficking of this source of free cholesterol. Our approach was to measure the effect of mob

• Both subcutaneous s c and mucosal administration of

  2023-09-04

  

  Both subcutaneous (s.c.) and mucosal administration of short synthetic peptide derivatives of AChR prevent the onset of EAMG, but do not treat ongoing EAMG [80], [81], [82], [83], [84], [85]. The selection of peptides for treatment is mainly based on the identification of immunodominant T- and B-cel

• Casein accounts for of the total protein

  2023-09-04

  

  Casein accounts for 80% of the total protein in bovine milk (Capriotti, Cavaliere, Piovesana, Samperi, & Laganà, 2016); hydrolysates or bioactive peptides derived from casein have been employed widely in food as a functional ingredient (Capriotti et al., 2016, Field et al., 2008). Many studies have

14720 records 233/982 page Previous Next First page 上5页 231232233234235 下5页 Last page